Trial Profile
Phase II study of erlotinib monotherapy versus in erlotinib in combination with nab-paclitaxel, in patients with epidermal growth factor receptor wild-type non-small-cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2015
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Sep 2015 New trial record